Growth Metrics

TriSalus Life Sciences (TLSI) Asset Writedowns and Impairment (2024 - 2025)

TriSalus Life Sciences posted quarterly Asset Writedowns and Impairment of $34000.0 for Q3 2025, down 40.35% on a QoQ basis from $57000.0 in Q2 2025.

TriSalus Life Sciences (TLSI) has 2 years of Asset Writedowns and Impairment data on file, last reported at $34000.0 in Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Sep 2025 stood at $317000.0 (changed N/A YoY), and the FY2024 full-year result was $187000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 stood at $34000.0, down from $57000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $187000.0 in Q4 2024 and bottomed at $34000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 TriSalus Life Sciences 187.09 Mn 130.54 Mn 7.67 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 34,000.00
Sep 30, 2025 34,000.00
Jun 30, 2025 57,000.00
Jun 30, 2025 57,000.00
Mar 31, 2025 39,000.00
Mar 31, 2025 39,000.00
Dec 31, 2024 187,000.00
Dec 31, 2024 187,000.00